Results 51 to 60 of about 42,556 (220)

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer

Nature Communications
Cancer cells counteract oxidative stress through upregulation of antioxidant networks. Peroxiredoxin 3 (PRX3), a mitochondrial antioxidant enzyme, regulates reactive oxygen species homeostasis and promotes tumor cell survival.
Victoria Gibson, Joanna Dzialo, Terri Messier, Aleksandra Bzura, Charlotte Poile, Jan Rogel, Jens C. Hahne, Aida Habibovic, Stephanie Stead, Alexis Saaman, Kevin G. Blyth, Peter W. Szlosarek, Simon Lord, Fiona Thistlethwaite, Min Zhang, Apostolos Nakas, Peter Wells-Jordan, Kudzayi Kutywayo, Kelly J. Butnor, Nicholas. H. Heintz, George N. Naumov, Maurice Dungey, Julio Herrero Colomina, Burak Aktas, Sean Dulloo, James Spicer, Dean A. Fennell, Brian Cunniff   +27 more
doaj   +1 more source

Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. [PDF]

PLoS ONE, 2009
BACKGROUND: Malignant pleural mesothelioma is considered an almost incurable tumour with increasing incidence worldwide. It usually develops in the parietal pleura, from mesothelial lining or submesothelial cells, subsequently invading the visceral ...
Oluf Dimitri Røe, Endre Anderssen, Eli Helge, Caroline Hild Pettersen, Karina Standahl Olsen, Helmut Sandeck, Rune Haaverstad, Steinar Lundgren, Erik Larsson   +8 more
doaj   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, EarlyView.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Circulating SMRP and CA‐125 before and after pleurectomy decortication for pleural mesothelioma

Thoracic Cancer
Background Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin‐related protein (SMRP) and cancer antigen 125 (CA‐125) are established blood‐based biomarkers for monitoring PM.
Juuso Paajanen, Ahmed Sadek, William G. Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R. Gill, Raphael Bueno   +8 more
doaj   +1 more source

Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation

Case Reports in Oncological Medicine, 2013
Introduction. Pleural mesothelioma with metastasis to the subcutaneous tissue of the abdominal wall at first diagnosis and without penetration into the peritoneum is an extremely rare clinical presentation. Methods.
R. F. Falkenstern-Ge, M. Kimmich, S. Bode-Erdmann, G. Friedel, G. Ott, M. Kohlhäufl   +5 more
doaj   +1 more source

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma

Journal of Translational Medicine, 2023
Mesothelioma is a cancer typically caused by asbestos. Mechanistically, asbestos carcinogenesis has been linked to the asbestos-induced release of HMGB1 from the nucleus to the cytoplasm, where HMGB1 promotes autophagy and cell survival, and to the ...
Michele Carbone, Michael Minaai, Yasutaka Takinishi, Ian Pagano, Haining Yang   +4 more
doaj   +1 more source

Hypervision Proton Surgery: The Future Direction of Proton Therapy

iNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Clinical and Molecular Features of BAP1‐Mutated Meningiomas: Case Series

Molecular Carcinogenesis, EarlyView.
ABSTRACT BRCA1‐associated protein 1 (BAP1)‐deficient meningiomas represent a clinically and molecularly distinct subgroup with variable histology and aggressive behavior that may not be fully captured by current grading criteria. The clinical spectrum of BAP1 alterations in meningiomas, including both somatic and germline contexts, remains incompletely
Ivan Pradilla, Rasha Alfattal, Susan L. McGovern, Shaan M. Raza, Franco DeMonte, Leomar Y. Ballester, Chirag B. Patel, Carlos Kamiya‐Matsuoka   +7 more
wiley   +1 more source

Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth

OncoImmunology, 2019
Versican promotes experimental tumor growth through cell- and non cell-autonomous mechanisms. Its role in mesothelioma progression has not been investigated so far.
Apostolos G. Pappas, Sophia Magkouta, Ioannis S. Pateras, Ioannis Skianis, Charalampos Moschos, Maria Eleni Vazakidou, Katherina Psarra, Vassilis G. Gorgoulis, Ioannis Kalomenidis   +8 more
doaj   +1 more source